Detailed results from Cytokinetics, Inc.'s Phase III SEQUOIA-HCM trial testing its cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM) have led some cardiologists to conclude the drug could have a competitive edge over Bristol Myers Squibb’s rival myosin inhibitor Camzyos (mavacamten).
Key Takeaways
-
Cardiologists at Heart Failure 2024 were enthusiastic about Cytokinetics’ cardiac myosin inhibitor aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM).
-
Some doctors said myosin inhibitors are poised to replace beta blockers as standard of care and aficamten could have advantages over Bristol’s Camzyos, approved in 2022
Cytokinetics presented the data in a late-breaking session at the International Congress of the European Society of Cardiology’s Heart Failure meeting in Lisbon on 13 May, coinciding with a publication in the New England Journal of Medicine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
